+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 100Years
FEMALE
ID01799538

Comparing Nebulized and Inhaled Albuterol to Improve Lung Function in Women with Lymphangioleiomyomatosis

Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-10-29

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Lymphangioleiomyomatosis LAM is a rare lung disease that mainly affects women, causing muscle tissue to grow in the lungs and block airflow. This progressive disease can lead to severe breathing problems and may even require a lung transplant. Researchers are evaluating whether inhaled albuterol delivered by a nebulizer or a metered dose inhaler MDI better improves lung function in women with LAM. Participants in this study will be randomly assigned to receive albuterol either via a nebulizer or through two or four puffs of a metered dose inhaler across three consecutive days. The study includes a 3-day overnight stay during which treatments are administered around the same time each day. Higher doses of albuterol than usual are tested with the inhaler. Lung function tests are performed before and after each treatment to measure changes. Women aged 18 and older with impaired lung function due to LAM will be involved. Screening includes a physical exam and medical history, and participants must stop long-acting inhalers one week before the study. Researchers will track lung function improvements over the 3 days to compare the two delivery methods. The primary outcome is the difference in lung function after treatment. The total study period extends until November 2027.

CONDITIONS

Brief Title

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

Research Team

T

Tatyana A Worthy, R.N.

J

Joel Moss, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here